


FPG ASIAN



FPG NON ASIAN





Figure S1: Meta-analysis of placebo-controlled randomized clinical trials that investigated the effects of SGLT2is on fasting plasma glucose in Asian and non-Asian patients with T2DM insufficiently controlled on metformin monotherapy.

Cana: canagliflozin. Dapa: dapagliflozin. Empa: empagliflozin. Ertu: ertugliflozin. Ipra: ipragliflozin. Tofo: tofogliflozin.

The figure after each medication name corresponds to the daily dose in mg.

CI: confidence interval. FPG: fasting plasma glucose. IV: inverse variance. SD: standard deviation. SGLT2i: sodium-glucose cotransporter type 2 inhibitor.

BW ASIAN



BW NON ASIAN





Figure S2: Meta-analysis of placebo-controlled randomized clinical trials that investigated the effects of SGLT2is on body weight in Asian and non-Asian patients with T2DM insufficiently controlled on metformin monotherapy.

Cana: canagliflozin. Dapa: dapagliflozin. Empa: empagliflozin. Ertu: ertugliflozin. Ipra: ipragliflozin. Tofo: tofogliflozin.

The figure after each medication name corresponds to the daily dose in mg.

BW: body weight. CI: confidence interval. IV: inverse variance. SD: standard deviation. SGLT2i: sodium-glucose cotransporter type 2 inhibitor.

SBP ASIAN



SBP NON ASIAN




Figure S3: Meta-analysis of placebo-controlled randomized clinical trials that investigated the effects of SGLT2is on systolic blood pressure in Asian and non-Asian patients with T2DM insufficiently controlled on metformin monotherapy.

Cana: canagliflozin. Dapa: dapagliflozin. Empa: empagliflozin. Ertu: ertugliflozin. Ipra: ipragliflozin. Tofo: tofogliflozin.

The figure after each medication name corresponds to the daily dose in mg.

CI: confidence interval. IV: inverse variance. SD: standard deviation. SBP: systolic blood pressure. SGLT2i: sodium-glucose cotransporter type 2 inhibitor.